TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02009709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin 0.1% ophthalmic solution
Description: Instillation of 0.1% riboflavin ophthalmic solution, one drop every 3 minutes for 30 minutes before the procedure and one drop every 3 minutes during the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin 0.1% ophthalmic solution
Description: Instillation of 0.1% riboflavin ophthalmic solution, one drop every 3 minutes for 30 minutes before the procedure and one drop every 3 minutes during the procedure.
Study: NCT02577809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: 100mg Indomethacin suppository

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: 100mg Indomethacin suppository
Study: NCT01307982

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrojejunal (GJ) feeding tube
Description: Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
Study: NCT00352339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rispridoen and Aripiprazole
Description: Start with risperidone and switch it to aripiprazole. Flexible dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidne
Description: Start with risperidne and keep it through the end of study. Risperidne:flexible dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abilify
Description: Start with abilify and keep it through the end of study
Study: NCT03951155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Relaxation
Description: * Ask the child to lie down in a comfortable position. Ask him/her to notice how their muscles feel in each part of the body. Taking one area of the body at a time (face, shoulders, arms, hands, fingers, abdomen, legs, feet, and toes).~* Instruct the child to contract the muscles for 5 seconds, take a deep breath, and release.~* Next, instruct the child to contract all muscles simultaneously, hold for 5 seconds, then release.~* Finally, ask him/her to notice how his/her muscles feel after the exercise.
Study: NCT00400764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulanermin
Description: Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulanermin
Description: Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulanermin
Description: Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulanermin
Description: Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was administered by intravenous (IV) infusion at 375 mg/m\^2 weekly for up to eight doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab was administered by intravenous (IV) infusion at 375 mg/m\^2 weekly for up to eight doses.
Study: NCT04198012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemoCare™ Hemodialysis System
Description: The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
Study: NCT01417767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG regimen
Description: cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-aza-deoxycytidine
Description: Decitabine (5-aza-deoxycytidine)for injection, 20mg/m2/day, IV (in the vein) on days 1-5 of each 28 day cycle, Number of Cycles: 2.
Study: NCT01245608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypill
Description: Polypill taken once daily for 5 years. Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg
Study: NCT04349969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117+AK104
Description: All Subjects will receive 3 weekly infusions of AK117 (Days 1, 8, and 15) and 1 infusion of AK104 (on Day 1) as combination therapy in each 21-day treatment cycle until unacceptable toxicity, documentation of confirmed PD, or subject withdrawal.
Study: NCT04049513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WZTL002-1 (1928T2z CAR-T cells)
Description: WZTL-002 comprises autologous third-generation anti-CD19 chimeric antigen receptor T-cells (termed 1928T2z). The chimeric antigen receptor in WZTL-002 incorporates the FMC63 anti-CD19 soluble chain variable fragment extracellularly, and portions of both CD28 and the Toll/interleukin-1 receptor (TIR) domain of Toll Like Receptor 2 (TLR2) as intracellular co-stimulatory domains, alongside CD3ζ. WZTL-002 (autologous 1928T2z CAR T-cells) will be administered on D0 as a single IV infusion, following lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
Description: Cyclophosphamide 500 mg/m\^2 IV on days -5 to -3, inclusive. Fludarabine 30 mg/m\^2 IV on days -5 to -3, inclusive
Study: NCT02239003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Study: NCT02117401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg
Study: NCT02009709

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CCL-VARIO UV lamp
Description: Application of ultraviolet light on the eye to be treated at an irradiance of 9 mW/cm2 for 10 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CCL-VARIO at 18 mW/cm2
Description: Application of ultraviolet light on the eye to be treated at an irradiance of 18 mW/cm2 for 5 minutes.
Study: NCT02117401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg
Study: NCT02239003

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00514189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cells
Description: The first vaccination will be given once your blood counts have recovered from the final dose of chemotherapy. The remaining 3 vaccinations will be given every 28 days (+/- 7 days).
Study: NCT02527512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Solution of 0.90% w/v of NaCl, 308 mOsm/L or 9.0 g per liter
Study: NCT03917615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor contraction
Description: Ultrasound examination will be performed to asses urinary bladder displacement being a marker for pelvic floor muscle function

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor contraction
Description: Ultrasound examination will be performed to asses urinary bladder displacement being a marker for pelvic floor muscle function
Study: NCT01859013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose for the remainder of the trial.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken orally once daily in the evening for the first two weeks, and orally twice daily (AM and PM) for the remainder of the study.
Study: NCT01542892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Supplement Intervention
Description: Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement Intervention
Description: Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
Study: NCT02978495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorrubicin 60 mg/m2 4 cycles each 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorrubicin 60 mg/m2 4 cycles each 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorrubicin 60 mg/m2 4 cycles each 21 days
Study: NCT02117401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg
Study: NCT02978495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorrubicin 60 mg/m2 4 cycles each 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 1,5 once a week, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 1,5 once a week, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 weekly for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80mg/m2 weekly for 12 weeks
Study: NCT02117401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min
Study: NCT02978495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 weekly for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80mg/m2 weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m2 4 cycles each 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600mg/m2 4 cycles each 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600mg/m2 4 cycles each 21 days
Study: NCT02978495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600mg/m2 4 cycles each 21 days
Study: NCT03333187

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib continuous therapy
Study: NCT00400764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was administered by intravenous (IV) infusion at 375 mg/m\^2 weekly for up to eight doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was administered by intravenous (IV) infusion at 375 mg/m\^2 weekly for up to eight doses.
Study: NCT00244985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: IV
Study: NCT03325231

Intervention type: OTHER
Intervention: Reconstructive surgery following bladder removal.
Description: Investigating patient experience of bladder reconstructions.
Study: NCT02329587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERP plus tDCS
Description: Participants in the ERP plus tDCS arm will receive an 11-session program, including 10 sessions which include both tDCS and ERP. During these sessions, 20 minutes of anodal tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERP plus sham tDCS
Description: Participants in the ERP plus sham tDCS arm will receive an 11-session program, including 10 sessions which include both sham tDCS and ERP. During these sessions, 20 minutes of sham tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
Study: NCT02457065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Melanoma Survivor plaque
Description: The investigators give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors.
Study: NCT01554904

Intervention type: DEVICE
Group type: OTHER
Intervention: Facial-Flex
Description: Oral exercise device
Study: NCT00654355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus ointment
Description: tacrolimus ointment to be applied twice daily to affected areas during duration of study
Study: NCT01940055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual task treadmill walking exercise program
Description: Participants will receive 5 minute warm up and cool down session followed by a 30 minute dual task program which includes treadmill walking while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Treadmill speed will be set so as to not exceed 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dual task recumbent cycling exercise program
Description: Participants will receive a 5 minute warm up and cool down session followed by a 30 minute dual task exercise program which includes recumbent cycling while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Recumbent cycling speed will be set so as to achieve 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
Study: NCT02553096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACCESS
Description: The ACCESS system consists of a smartphone, a pulse-oximeter, a spirometer and a forehead thermometer. Questions concerning changes in symptoms, physical limitations and emotions are answered by touch screen on the smartphone, complemented by measurements of the pulse-oximeter, spirometer and thermometer. Based on this information, the system calculates the current risk of an exacerbation and, when applicable, the participant will receive personalized instructions about which actions to take in order to manage the exacerbation. Participants are instructed to use ACCESS in case of symptom worsening.
Study: NCT04164927

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lymphatic Drainage
Description: 1. Lymphatic correction method was used via the KinesioTaping® to patients group.~2. Standardized 30-minute Manuel Lymphatic Drainage treatment was applied to the MLD group.~3. Control group received only physiotherapy treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Description: Depending on the size of the leg two or three fan cut tapes were applied with light paper-off tension on the frontal, medial and lateral aspects of the limb. Kinesio taping was applied by certified Kinesio Tape practitioner once a week to Kinesiotaping group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures. These exercises were undertaken in sets of 10 repetitions, 3 times daily; the physiotherapist was present to assist, as required, on 2 occasions per day for the first 3 postoperative days and then once daily from day 4 until hospital discharge.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures. These exercises were undertaken in sets of 10 repetitions, 3 times daily; the physiotherapist was present to assist, as required, on 2 occasions per day for the first 3 postoperative days and then once daily from day 4 until hospital discharge.
Study: NCT02889874

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Omission of radiation therapy
Description: Omission of radiation therapy (adjuvant endocrine therapy only).
Study: NCT03161873

Intervention type: DEVICE
Intervention: Ava
Description: Ava is a fertility monitoring bracelet that collects various physiological parameters

Intervention type: DEVICE
Intervention: Ava
Description: Ava is a fertility monitoring bracelet that collects various physiological parameters

Intervention type: DEVICE
Intervention: Ava
Description: Ava is a fertility monitoring bracelet that collects various physiological parameters

Intervention type: DEVICE
Intervention: Ava
Description: Ava is a fertility monitoring bracelet that collects various physiological parameters
Study: NCT02305992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Block with 0.5% Ropivicaine
Description: Axillary blocks are regional anesthesia techniques that are sometimes employed as an alternative to general anesthesia for surgery of the shoulder, arm, forearm, wrist and hand. In this case, ultra-sound technique will be used.